Publication | Closed Access

IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo

Cell AutophagyBreast OncologyNovel TherapyMedicineAutophagySingle-agent Antitumor EfficacyImmune Checkpoint InhibitorBreast CancerTriple-negative Breast CancerAnti-cancer AgentRadiation OncologyOncologyCell BiologyTumor MicroenvironmentTumor Biology